Focusing on the Cannabis Administration and Opportunity Act (CAOA), the Marijuana Opportunity Reinvestment and Expungement Act (MORE), and the States Reform Act (SRA), our panelists will discuss how these proposals would change how the the relevant agencies (such as USDA, FDA, TTB, and PTO) regulate the cannabis sector.
Discover potential conflicts related to Federal agencies for marketers of Cannabis products, from limitations on intellectual property protection to agency enforcement action to litigation.
This panel seeks to address the pathways for federal cannabis reform in the 117th
Congress, considering legislative vehicles, political pragmatism, and actions of the
Administration.
Two DC insiders, Saphira Galoob, Managing Director of the Liaison Group, and Amber Littlejohn, Executive Director of the Minority Cannabis Business Association, will discuss a bird's-eye view of Democratic and Republican approaches to federal cannabis reform.
Focusing on the broad categories of Tax, Labor, Medical Cannabis, Constitutional Issues, and International, each area will be addressed by an expert practitioner.
Join us for a discussion of patents, patent rights, limitations of patents, and alternatives for protection, from utility to Plant Patents and PVP. Additionally, the panel will delve into deposit requirements (availability to 3rd parties and timing of deposit), data- quality, scope (written description/enablement), and the dynamics for Plant Patent-Flexibility and data quality requirements, and patent enforcement.
We’ll cover where the power to regulate/enforce gets vested, and through which agency/agencies, how cannabis becomes legalized: whether through legislation, ballot measures, or litigation, and the COVID Impact: what an “essential” designation means for cannabis as a driver of international economic development.